| Name | Niga-ichigoside F1 |
|---|---|
| Synonyms |
1-O-[(2α,3β)-2,3,19,23-Tetrahydroxy-28-oxours-12-en-28-yl]-β-D-glucopyranose
19α-hydroxyasiatic acid-28-O-β-D-glucopyrannoside β-D-Glucopyranose, 1-O-[(2α,3β)-2,3,19,23-tetrahydroxy-28-oxours-12-en-28-yl]- |
| Description | Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Niga-ichigoside F1 (2.5, 5, 10, 20 μM; for 24 hours) inhibits lipid accumu-lation in free fatty acid (FFA)-treated HepG2 cells in a dose-dependent manner. Niga-ichigoside F1 has no effects on cell viability[1]. Both nuclear and cytoplasmic Nrf2 expressions are lowered in Con, Niga-ichigoside F1 (20 μM), FFA (1 mM), and Niga-ichigoside F1 plus FFA treated Nrf2-silenced cells[1]. |
| In Vivo | Niga-ichigoside F1 (40 mg/kg; oral gavage; for 12 weeks) alleviates hepatic steatosis, possibly by significantly interacting with high-fat diet (HFD) to regulate lipid metabolism genes (including Srebp1c, Acc1, Fasn, Scd1, Cpt1a and Fabp5) in four-week-old male C57BL/6J mice[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 775.0±60.0 °C at 760 mmHg |
| Molecular Formula | C36H58O11 |
| Molecular Weight | 666.839 |
| Flash Point | 234.7±26.4 °C |
| Exact Mass | 666.397888 |
| LogP | 3.84 |
| Vapour Pressure | 0.0±6.0 mmHg at 25°C |
| Index of Refraction | 1.616 |
| Storage condition | 2-8℃ |